<DOC>
	<DOCNO>NCT02100618</DOCNO>
	<brief_summary>The purpose study establish long-term persistence immune response safety HPV vaccine healthy female age 9 25 year primary study ( NCT00541970 ) .</brief_summary>
	<brief_title>Antibody Persistence GlaxoSmithKline ( GSK ) Biologicals ' HPV-16/18 L1 VLP AS04 Vaccine ( GSK-580299 ) Administered Healthy Adults Adolescents , 6.5 Years After First Vaccination Primary Study</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Subjects , opinion investigator , comply requirement protocol subject ' parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] , opinion investigator , comply , requirement protocol . Subjects complete primary vaccination receive either two three dos GSK Biologicals ' HPV16/18 vaccine accord 0,6months schedule 0,1,6months schedule study HPV048 PRI ( 110659 ) ( NCT00541970 ) . A female , include , 9 14 year age 15 25 year age , time first vaccination , depend group belong study HPV048 PRI ( 110659 ) ( NCT00541970 ) , i.e. , 914 year old subject receive two dos GSK Biologicals ' HPV16/18 vaccine accord 0,6months schedule 1525 year old subject receive three dos GSK Biologicals ' HPV16/18 vaccine accord 0,1,6months schedule . Written inform consent obtain subject/from parent ( ) /LAR ( ) subject . In addition , subject legal age consent sign personally date write informed assent form . Healthy subject establish medical history clinical examination enter study . Child care . Use investigational nonregistered product ( drug vaccine ) HPV16/18 study vaccine administer study HPV048 PRI ( 110659 ) ( NCT00541970 ) last visit primary study current study visit plan use study period . Administration HPV vaccine last visit primary study current study visit plan use study period . Chronic administration ( defined 14 day total ) immunosuppressant immunemodifying drug within three month prior blood sampling . Inhaled topical steroid allow . Planned administration/administration vaccine foreseen study protocol within period start 30 day study entry , exception routine meningococcal , inactivate influenza , hepatitis B , diphtheria/tetanus and/or diphtheria/tetanuscontaining , poliomyelitis and/or pertussis vaccine 8 day study entry . Enrolment defer subject outside specify window . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Cancer autoimmune disease treatment . Administration immunoglobulins and/or blood product within 3 month precede blood sampling .</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>32 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Adolescents</keyword>
	<keyword>Adults</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>6.5 year</keyword>
	<keyword>Safety</keyword>
	<keyword>Antibody persistence</keyword>
	<keyword>Human Papillomavirus ( HPV ) vaccine</keyword>
</DOC>